Comparative Bioavailability Study of Two Tablet Formulations of Digoxin

Journal of Immunoassay and Immunochemistry

Volumn 25, Issue 2, 2004, Pages 125-133

  Aboul Enein, Hassan Y ^a   Abou Basha, Laila I ^b   Wahman, Lobna F ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

Author keywords

Bioavailability; Bioequivalence; Cardixin; Digoxin specific antibodies; Lanoxin

Indexed keywords

CARDIXIN; DIGOXIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIGOXIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; TABLETS; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 2342525942     PISSN: 15321819     EISSN: None     Source Type: Journal    
DOI: 10.1081/IAS-120030522     Document Type: Article

References (11)

1. Reynolds, J.E.F. Martindale. The Extrapharmacopaeia, 29th Ed.; Pharmaceuticals Press: London, 1989; 828.
2. Goodman & Gilman. The Pharmacological Basis of Therapeutics; Hardman, J.G., Gilman, A.G., Limbird, L.E., Eds.; McGraw-Hill Co.: New York, NY, 2001.
3. Cuena Boy, R.; Ortiz de Apodaca Ruiz, M.A.; Macia Martinez, M.A. Best result of digoxin dosing in the aged by taking into account that both the elimination as well as the volume of distribution of the drug decrease when the kidney function deteriorates. Anales de Medicina Interna 2002, 19, 331-335.
4. Aronson, J.K. Clinical pharmacokinetics of digoxin. Clin. Pharmacokin. 1980, 5, 137-149.
5. Moffat, A.C.; Jackson, J.V.; Moss, M.S.; Widdop, B. Clarke's Isolation and Identification of Drugs in Pharmaceuticals Body Fluids and Post Mortem Materials, 2nd Ed.; Pharmaceutical Press: London, 1986; 425.
6. The United States of Pharmacopoeia 23/National Formulary 18, U.S. Pharmacopial Conversion, Rockville, MD, 1995.
7. WHO: Drug Information; 1994; Vol. 8, No. 2.
8. WHO: Drug Information; WHO: Helsinki Declaration; 1992; Vol. 6, No. 4.
9. Hauschke, D.; Steinijans, V.W.; Dilenl, E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Therap. Toxicol. 1990, 28, 72-78.
10. Schulz, H.U.; Steinijans, V.W. Striving for standards in bioequivalence assessment. A review. Int. J. Clin. Pharmacol. Therapy & Toxicol. 1992, 30 (Suppl. 1), S1-S6.
11. Henderson, J.D.; Esham, R.H. Generic issues for problematic drugs. Southern Med. J. 2001, 94, 16-21.